Asymmetry Capital Management L.P. Purchases New Stake in Kadmon Co. (KDMN)
Asymmetry Capital Management L.P. purchased a new position in shares of Kadmon Co. (NYSE:KDMN) in the first quarter, HoldingsChannel.com reports. The fund purchased 199,147 shares of the company’s stock, valued at approximately $846,000.
A number of other institutional investors and hedge funds have also bought and sold shares of KDMN. Bank of New York Mellon Corp purchased a new position in Kadmon during the 3rd quarter worth approximately $119,000. Wells Fargo & Company MN raised its position in Kadmon by 23.2% during the 3rd quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock worth $247,000 after buying an additional 13,923 shares during the last quarter. AE Wealth Management LLC raised its position in Kadmon by 61.1% during the 4th quarter. AE Wealth Management LLC now owns 520,713 shares of the company’s stock worth $1,885,000 after buying an additional 197,552 shares during the last quarter. BlackRock Inc. raised its position in Kadmon by 151.2% during the 4th quarter. BlackRock Inc. now owns 208,190 shares of the company’s stock worth $754,000 after buying an additional 125,308 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new position in Kadmon during the 4th quarter worth approximately $868,000. 61.46% of the stock is owned by institutional investors.
Several equities analysts have recently weighed in on the stock. Piper Jaffray reaffirmed a “positive” rating and set a $9.00 target price (up from $7.00) on shares of Kadmon in a report on Tuesday, February 13th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon in a report on Friday, March 9th. Jefferies Group lifted their target price on shares of Kadmon to $16.00 and gave the company a “buy” rating in a report on Tuesday, February 13th. Zacks Investment Research lowered shares of Kadmon from a “buy” rating to a “hold” rating in a report on Friday, May 4th. Finally, ValuEngine raised shares of Kadmon from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Kadmon currently has an average rating of “Hold” and a consensus target price of $11.55.
Kadmon (NYSE:KDMN) last posted its earnings results on Tuesday, May 8th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.03. The firm had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $2.67 million. sell-side analysts anticipate that Kadmon Co. will post -1.12 earnings per share for the current year.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Want to see what other hedge funds are holding KDMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kadmon Co. (NYSE:KDMN).
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.